Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Warning Letter On Adverse Event Reporting May Stem As Much From Jazz Reaction As REMS Problem

This article was originally published in The Pink Sheet Daily

Executive Summary

Jazz Pharmaceuticals initially admitted it had known about 10 deaths and 64 other serious, unexpected adverse drug experiences associated with its cataplexy drug Xyrem, but later changed its story, FDA says.

You may also be interested in...

Adverse Event Reports From Acorda Languished As Long As 100 Days, FDA Finds

FDA warning letter says the company did not report all complaints about the lack of efficacy of its muscular sclerosis drug Ampyra.

Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture

FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts